CVRx to Attend Upcoming Investor Conferences

Rhea-AI Summary

CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will participate in two investor conferences on November 17, 2022, in New York, NY. The conferences include the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the 13th Annual Craig-Hallum Alpha Select Conference. CVRx's flagship product, Barostim, is the first FDA-approved technology aimed at treating heart failure through neuromodulation, and it has also received CE Mark approval in Europe.

MINNEAPOLIS, Nov. 03, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the following upcoming investors conferences on Thursday, November 17, 2022:

Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Location: New York, NY

13^th Annual Craig-Hallum Alpha Select Conference
Location: New York, NY

For more information on the conferences or to schedule a one-on-one meeting with CVRx, please contact your respective Canaccord Genuity or Craig-Hallum representative, or CVRx's investor relations at ir@cvrx.com.

About CVRx, Inc.
CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
ICR Westwicke
443-213-0501
ir@cvrx.com

Media Contact:
Erich Sandoval
Finn Partners
212-867-1762
erich.sandoval@finnpartners.com

FAQ

What is the significance of CVRx participating in the conferences on November 17, 2022?

CVRx's participation highlights its commitment to engage with investors and showcase its innovative neuromodulation solutions.

Where will CVRx hold its investor conferences?

The investor conferences will take place in New York, NY.

What are the names of the conferences CVRx is attending?

CVRx will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the 13th Annual Craig-Hallum Alpha Select Conference.

What is Barostim and why is it important?

Barostim is an FDA-approved medical device that uses neuromodulation to treat heart failure, improving patient outcomes.

Has Barostim received any special recognitions or approvals?

Yes, Barostim has received FDA Breakthrough Device designation and CE Mark approval for use in heart failure and resistant hypertension.